pcmr12039-sup-0001-Supplementary-Material.docxWord document13441K

Data S1. Materials and Methods.

Figure S1. Chi-square test for differences in nuclear Dicer staining at different stages of melanoma progression.

Figure S2. Tissue microarray staining using a second monoclonal anti-Dicer antibody (Clonegene).

Figure S3. Monoclonal antibody against Dicer (Clonegene) confirms the positive correlation between nuclear Dicer expression and melanoma patient survival.

Figure S4. Cytoplasmic and nuclear signals of monoclonal anti-Dicer antibody are impeded by the blocking peptide, compared with staining with anti-Dicer antibody alone.

Table S1. Nuclear Dicer staining and clinicopathologic characteristics of 262 primary melanomas (Sigma antibody).

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.